Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer that can be difficult to diagnose. It is most commonly found in elderly individuals and can be found in any area of the body. AFX is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration. Despite its rarity, it is important for doctors to be aware of the signs and symptoms of AFX, as early diagnosis and treatment are critical for successful outcomes.
Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer. It is a type of soft-tissue sarcoma, which is a cancer that develops in the connective tissues of the body. AFX is most commonly found in elderly individuals and can be found in any area of the body, although it is most commonly found on the head or neck. It is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration.
The most common sign of AFX is a rapidly growing, red-brown to yellow-brown papule or nodule. This lesion may be tender to the touch and may have a central ulceration. Other signs and symptoms of AFX may include itching, bleeding, and pain. The lesion may also be accompanied by a reddish-brown halo or a crusty, flaky surface.
Diagnosis of AFX begins with a physical examination. During the physical exam, the doctor will examine the lesion and may take a biopsy. A biopsy is a procedure in which a small sample of the lesion is removed and sent to a laboratory for further examination. The laboratory will examine the sample under a microscope and may order additional tests to confirm the diagnosis.
The primary treatment for AFX is surgical excision. This involves surgically removing the lesion and any surrounding tissue. In some cases, radiation therapy may be used to reduce the size of the lesion prior to surgery. In cases where the lesion is too large to be removed surgically, chemotherapy may be used to shrink the tumor.
Unfortunately, there is no known way to prevent AFX. However, it is important to practice sun safety and to avoid prolonged exposure to ultraviolet (UV) radiation. This includes wearing sunscreen and protective clothing when outdoors, avoiding tanning beds, and avoiding direct sun exposure during peak UV hours. Additionally, it is important to monitor any changes in the skin and to seek medical attention if any suspicious lesions are found.
Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer that can be difficult to diagnose. It is most commonly found in elderly individuals and can be found in any area of the body. AFX is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration. Early diagnosis and treatment are critical for successful outcomes, so it is important for doctors to be aware of the signs and symptoms of AFX. While there is no known way to prevent AFX, it is important to practice sun safety and to monitor any changes in the skin.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Lung Transplant for Lung Cancer: Promising, in Rare Cases
3.
Rural-urban disparities seen in cervical cancer
4.
Obesity linked to subsequent neoplasms in childhood cancer survivors
5.
New policy review highlights the importance of health-related quality of life in advanced cancer
1.
Empowering Oncology with Data: Cloud Security, Real-World Evidence, and Clinical Insights
2.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
3.
Is AI The New Radiologist For Breast MRI?
4.
Pediatric Oncology at the Cutting Edge: From Early Diagnosis to Lifesaving Therapies
5.
Bone Marrow Regeneration in Hematologic Recovery
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part VI
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VI
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation